



# Essai Clinique

Généré le 05 mai 2024 à partir de

|                         |                                                                                                                                                                                                                                                                                                                                                                                                   |
|-------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Titre                   | A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy                                                                                                                                                                      |
| Protocole ID            | KRYSTAL-10                                                                                                                                                                                                                                                                                                                                                                                        |
| ClinicalTrials.gov ID   | <a href="https://clinicaltrials.gov/ct2/show/study/NCT04793958">NCT04793958</a>                                                                                                                                                                                                                                                                                                                   |
| Type(s) de cancer       | Côlon et rectum                                                                                                                                                                                                                                                                                                                                                                                   |
| Phase                   | Phase III                                                                                                                                                                                                                                                                                                                                                                                         |
| Type étude              | Clinique                                                                                                                                                                                                                                                                                                                                                                                          |
| Médicament              | MRTX849 en association avec le cétuximab versus une chimiothérapie                                                                                                                                                                                                                                                                                                                                |
| Institution             | CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL<br> PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX<br>5415 boul. de l'Assomption, Montréal, QC, H1T2M4                                                                                                                                                                              |
| Ville                   |                                                                                                                                                                                                                                                                                                                                                                                                   |
| Investigateur principal | Dr Mikaël Soucisse                                                                                                                                                                                                                                                                                                                                                                                |
| Coordonnateur           | Audrey Lamoureux<br>514-252-3400 poste 6258                                                                                                                                                                                                                                                                                                                                                       |
| Statut                  | Fermé                                                                                                                                                                                                                                                                                                                                                                                             |
| Date d'activation       | 20-07-2022                                                                                                                                                                                                                                                                                                                                                                                        |
| But étude               | Study 849-010 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with CRC with KRAS G12C mutation.                                                                                                                                             |
| Critères d'éligibilité  | <ul style="list-style-type: none"><li>• Histologically confirmed diagnosis of colorectal carcinoma with KRAS G12C mutation in tumor tissue.</li><li>• Prior receipt of 1st line treatment in advanced CRC with a fluoropyrimidine-based chemotherapy regimen containing either oxaliplatin or irinotecan, and radiographically documented progression of disease on or after treatment.</li></ul> |
| Critères d'exclusion    | <ul style="list-style-type: none"><li>• Prior treatment with a therapy targeting KRAS G12C mutation (e.g., AMG 510).</li><li>• Prior treatment with an anti-EGFR antibody (e.g., cetuximab or panitumumab).</li><li>• Active brain metastasis</li></ul>                                                                                                                                           |